Stockscreener 앱 받기
10.10
0.45%
0.0451
전일 마감가:
$10.05
열려 있는:
$10.1
하루 거래량:
30,341
Relative Volume:
0.08
시가총액:
$575.33M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-8.4126
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
-1.70%
1개월 성능:
+5.49%
6개월 성능:
+86.26%
1년 성능:
+154.28%
1일 변동 폭
$9.92
$10.21
1주일 범위
$9.91
$10.59
52주 변동 폭
$2.60
$10.97
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.10 | 572.49M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
494.23 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
800.45 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
836.88 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.93 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
349.91 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Oppenheimer | Outperform |
| 2025-12-03 | 개시 | Craig Hallum | Buy |
| 2025-12-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Fund Flows: Does Equinox Gold Corp have declining or rising EPSInflation Watch & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Trading Action: What is the long term forecast for Design Therapeutics Inc stockDip Buying & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Retail Surge: Is Design Therapeutics Inc attractive for institutional investorsJuly 2025 Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery - Business Wire
Published on: 2026-02-07 15:17:14 - baoquankhu1.vn
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView
Design Therapeutics announces governance-driven board resignation - TipRanks
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why - Defense World
Published on: 2026-02-01 06:18:16 - baoquankhu1.vn
How volatile is Design Therapeutics Inc. stock2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Loss Report: How volatile is Design Therapeutics Inc stockEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn
Design Therapeutics, Inc. Announces Resignation of Deepa Prasad from the Company's Board of Directors, Effective February 1, 2026 - marketscreener.com
Design Therapeutics (NASDAQ:DSGN) Shares Gap UpStill a Buy? - MarketBeat
Recap Report: Does Design Therapeutics Inc meet Warren Buffetts criteria2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Insider Sell: Can Design Therapeutics Inc expand its profit marginsBond Market & AI Enhanced Trading Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Bear Alert: Is Design Therapeutics Inc attractive for institutional investorsTrade Performance Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics - BioSpace
Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Business Wire
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Yahoo Finance
Design Therapeutics (NASDAQ:DSGN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Trading Recap: Will Bullfrog AI Holdings Inc Equity Warrant stock recover after earningsQuarterly Profit Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighHere's What Happened - MarketBeat
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad - The AI Journal
Fuchs Dystrophy Clinical Trial Outlook: 5+ Companies and 7 Emerging Therapies Reshape the Global Treatment Pipeline, Says DelveInsight - Barchart.com
Fuchs Dystrophy Clinical Trial Outlook: 5+ Companies and 7 - openPR.com
Fuchs Endothelial Corneal Dystrophy Clinical Trial Pipeline - openPR.com
Is Design Therapeutics Inc. stock heavily shortedEarnings Summary Report & Weekly Chart Analysis and Trade Guides - bollywoodhelpline.com
Can Design Therapeutics Inc. stock beat market expectations this quarterStop Loss & Verified High Yield Trade Plans - bollywoodhelpline.com
Design Therapeutics (NASDAQ:DSGN) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Shares Down 6.5%Time to Sell? - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq Futures Research-Driven Model - Kalkine Media
Design Therapeutics (DSGN) Price Target Increased by 10.64% to 13.26 - Nasdaq
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network
insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design - Business Wire
Relmada Therapeutics Provides Regulatory Update Confirming - GlobeNewswire
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why - MSN
Press Release Service: Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases - CRISPR Medicine News
Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases - BioSpace
Can Protara Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Design Therapeutics (NASDAQ:DSGN) Shares Down 10%What's Next? - MarketBeat
Los Angeles Daily NewsDesign Therapeutics, Inc.Common Stock (Nasdaq:DSGN) Stock Quote - FinancialContent
Resistance Break Could Fuel Sailani Tours N Travels Limited RallyEnergy Sector Updates & High Profit Investment Ideas - bollywoodhelpline.com
Oppenheimer Initiates Coverage of Design Therapeutics (DSGN) with Outperform Recommendation - Nasdaq
Design Therapeutics, Inc.Common Stock (NQ: DSGN - FinancialContent
Oppenheimer Initiates Design Therapeutics at Outperform With $18 Price Target - MarketScreener
Quarterly Recap: Is Design Therapeutics Inc stock a contrarian buyJuly 2025 Setups & Community Verified Trade Signals - Bộ Nội Vụ
What analysts say about Design Therapeutics Inc stockMarket Sentiment Shifts & Breakthrough Stock Performance - Early Times
2026 world cup analysis predictions: How sustainable is Design Therapeutics Inc. stock dividend payout2026 world cup usa national team round of 16 defensive leaders build up play tactical prediction statistical analysis - Улправда
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
2.08%
자본화:
|
볼륨(24시간):